首页> 外文OA文献 >Prophylactic antiviral therapy for hepatitis B virus surface antigen‐positive patients with diffuse large B‐cell lymphoma treated with rituximab‐containing chemotherapy

【2h】

Prophylactic antiviral therapy for hepatitis B virus surface antigen‐positive patients with diffuse large B‐cell lymphoma treated with rituximab‐containing chemotherapy

机译：乙型肝炎病毒表面抗原阳性促进型大B细胞淋巴瘤乙型肝炎病毒表面抗原阳性疗法治疗，用含生花青瘤化疗治疗

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Nobuhiko Yamauchi; Dai Maruyama; Ilseung Choi; Yoshiko Atsuta; Rika Sakai; Kazuho Miyashita; Yukiyoshi Moriuchi; Hideki Tsujimura; Nobuko Kubota; Go Yamamoto; Tadahiko Igarashi; Koji Izutsu; Shinichiro Yoshida; Kensuke Kojima; Toshiki Uchida; Yoshiko Inoue; Norifumi Tsukamoto; Eiichi Ohtsuka; Sachiko Suzuki; Yoko Inaguma; Satoshi Ichikawa; Hiroshi Gomyo; Yoko Ushijima; Kisato Nosaka; Mio Kurata; Yasuhito Tanaka; Ryuzo Ueda; Masashi Mizokami; Shigeru Kusumoto;
展开▼
作者单位

展开▼
年度 2021
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. The risk of hepatitis B virus reactivation and the role of antiviral prophylaxis in hepatitis B surface antigen negative/hepatitis B core antibody positive patients with diffuse large B-cell lymphoma receiving rituximab-based chemotherapy [J] . Lu Shasha, Xu Yu, Mu Qitian, Leukemia and lymphoma . 2015,第4期

机译：接受利妥昔单抗化疗的弥漫性大B细胞淋巴瘤患者中乙型肝炎病毒激活的风险和抗病毒预防在乙型肝炎表面抗原阴性/乙型肝炎核心抗体阳性患者中的作用
2. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis. [J] . Koo YX, Tay M, Teh YE, Annals of hematology . 2011,第10期

机译：接受含利妥昔单抗联合化疗但未常规抗病毒预防的乙型肝炎表面抗原阴性/乙型肝炎核心抗体阳性患者中乙型肝炎病毒（HBV）活化的风险。
3. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis [J] . Yu Xuan Koo, Matthew Tay, Yii Ean Teh, Annals of Hematology . 2011,第10期

机译：接受含利妥昔单抗联合化疗但未常规预防的乙型肝炎表面抗原阴性/乙型肝炎核心抗体阳性的乙型肝炎病毒（HBV）活化的风险
4. MALDI-TOF MS for Monitoring Drug Resistance in Hepatitis B Virus-Infected Patients during Antiviral Therapy [C] . Magda Rybicka, Piotr Stalke, Tomasz Smiatacz, International Mass Spectrometry Conference . 2014

机译：MALDI-TOF MS用于监测抗病毒治疗期间乙型肝炎病毒感染患者耐药性的MS
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival [O] . Kai-Lin Chen, Jie Chen, Hui-Lan Rao, 2015

机译：接受利妥昔单抗化疗的已解决的乙型肝炎弥漫性大B细胞淋巴瘤患者的乙型肝炎病毒活化和肝炎：危险因素和生存
7. A Case of Hepatitis B Virus Reactivation in a HBsAg-Negative and Anti-HBs-Positive Patient with Diffuse Large B-Cell Lymphoma after Rituximab plus CHOP Chemotherapy [O] . Han Min Park, Jae Yong Seo, Chung Jo Choi, 2014

机译：HBsAg阴性和抗HBS阳性患者乙型肝炎病毒重新激活的情况下，RITUXIMABAB加剁疗后弥漫性大B细胞淋巴瘤

Prophylactic antiviral therapy for hepatitis B virus surface antigen‐positive patients with diffuse large B‐cell lymphoma treated with rituximab‐containing chemotherapy

著录项

引文网络

相似文献

相关主题

期刊订阅